Clinical Trial Search

Primary: Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of…

Primary: Progression Free Survival (PFS) — 60 Weeks

Primary: Number of Participants Experiencing Serious Adverse Events and Non-serious Adverse Events

Primary: Number of Patients Experiencing Adverse Events — 22; 27 Participants

Primary: Pain on Visual Analog Scale (VAS) — 18; 35 mm

Primary: Overall Participant Counts Summarizing Adverse Events (AEs) During the Treatment Period — 65; 20; 9; 3 Participants

Primary: Subjects Who Experienced Relief of IBS Pain and Discomfort at Week 4 — 23; 18; 20 Participants

Primary: Safety and Tolerability of Drug, Assessed by Change in Methemoglobin Levels — 0.4; 0.5; 0.3; 0.3 Percent of Methemoglobin Level

Primary: Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco — 5; 4; 0 participants — p=0.77

Primary: Overall Survival for the Intent to Treat Population — 5.2; 6.8 months — p=0.2

Primary: Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 — 45; 29; 75; 92 percentage of participants

Primary: Percentage of Participants With Objective Response (OR)

Primary: Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE) — 4; 8; 12; 4 participants

Primary: Testosterone Area Below Baseline Interval — 21.0; 16.0; 54.6; 70.6 ng*days/mL

Primary: Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE) — 4; 20; 24; 2 participants